Press Releases


MOLOGEN is presenting two posters at International Cancer Immunotherapy Conference

The biotechnology company MOLOGEN AG is presenting two posters on the immunotherapies MGN1703 and MGN1601 at the Inaugural International Cancer Immunotherapy Conference (CRI-CIMT-EATI-AACR) in New York (September 16 – 19, 2015).

The first poster is outlining detailed pharmacokinetic and pharmacodynamic data from studies with the immunomodulator MGN1703 in healthy volunteers and cancer patients. The second poster is featuring immunological data from a study in renal cancer patients with the cell-based tumor vaccine MGN1601. 

Abstract details:

Title: "Pharmacokinetics and pharmacodynamics of the immunotherapeutic TLR9 agonist MGN1703 – conclusions by comparison of data from clinical trials with healthy volunteers and cancer patients" 

Poster presentation: September 16, 2015 from 7 p.m. to 9 p.m. in the Empire Ballroom 

Title: "Immune responses against tumor associated antigens are induced by treatment with the cell-based tumor vaccine MGN1601 in patients with renal cell carcinoma" 

Poster presentation: September 16, 2015 from 7 p.m. to 9 p.m. in the Empire Ballroom

For more information on the Inaugural International Cancer Immunotherapy Conference (CRI-CIMT-EATI-AACR) please visit the website


With new and unique technologies and active substances, the biotech company MOLOGEN is one of the pioneers in the field of immunotherapy. Alongside a focus on immuno-oncology, MOLOGEN also develops immunotherapies for the treatment of infectious diseases. 

The cancer immunotherapy MGN1703 is the company’s lead product and best-in-class TLR9 agonist. Treatment with MGN1703 triggers a broad and strong activation of the immune system. Due to this mechanism of action, MGN1703 has the potential to be applied to various indications. MGN1703 is currently being developed for first-line maintenance treatment of colorectal cancer (pivotal study) and small cell lung cancer (randomized controlled trial). Furthermore it is also being investigated in a phase I study in HIV. 

MOLOGEN’s pipeline focus is on new innovative immunotherapies to treat diseases for which there is a high medical need. 

MOLOGEN AG is listed on the stock exchange and its headquarters are located in Berlin, Germany. The shares of the company are listed on the Prime Standard at the Frankfurt Stock Exchange (ISIN DE0006637200).

Memberships in associations:

Biotechnologieverbund Berlin-Brandenburg (bbb) e.V. | BIO Deutschland e.V.  |  DECHEMA - Society for chemical technology and biotechnology e.V.  |  German industrial association of biotechnology (DIB)  |  Association for the Promotion of Science and Humanities in Germany  |  Association of German biotechnology companies (VBU)  |  Association of researching manufacturers of pharmaceuticals e.V. (VFA)  |  Association of the chemical industry e.V. (VCI)

MIDGE®, dSLIM®, EnanDIM® and MOLOGEN® are registered trademarks of MOLOGEN AG.


Claudia Nickolaus

Head of Investor Relations & Corporate Communications

Tel: +49 - 30 - 84 17 88 – 38

Fax: +49 - 30 - 84 17 88 - 50

Note about risk for future predictions

Certain information in this report contains forward-looking statements or the corresponding statements with negation or versions deviating from this or comparable terminology. These are described as forward-looking statements. In addition, all of the information given here that refers to planned or future results of business areas, key financial figures, developments of the financial situation or other financial figures or statistical data, is to be understood as such forward-looking statements. The company points out to investors that they should not rely on these forward-looking statements as predictions about actual future events. The company is not obligated and refuses to accept any liability for the forward-looking statements and has no obligation to update such statements in order to accurately reflect the current situation.

3 Questions to Dr. Söhngen

Dr. Mariola Söhngen CEO MOLOGEN AG

Claudia Nickolaus
Head of Investor Relations & Corporate Communications

T. +49 (0) 30 - 84 17 88 - 86
F. +49 (0) 30 - 84 17 88 - 50

[email protected]